US Bancorp DE Cuts Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

US Bancorp DE lowered its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 55.5% during the 3rd quarter, Holdings Channel reports. The firm owned 2,589 shares of the company’s stock after selling 3,228 shares during the quarter. US Bancorp DE’s holdings in CRISPR Therapeutics were worth $122,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. SFE Investment Counsel boosted its position in shares of CRISPR Therapeutics by 3.6% during the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after acquiring an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in CRISPR Therapeutics by 4.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after purchasing an additional 211 shares in the last quarter. Orion Capital Management LLC lifted its position in CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after purchasing an additional 220 shares during the last quarter. National Bank of Canada FI grew its stake in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $47.25 on Friday. CRISPR Therapeutics AG has a one year low of $43.42 and a one year high of $91.10. The firm’s fifty day moving average is $47.88 and its 200 day moving average is $52.04. The firm has a market cap of $4.03 billion, a PE ratio of -16.70 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the previous year, the business earned ($1.41) EPS. Research analysts predict that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRSP has been the subject of several analyst reports. Chardan Capital lowered their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Truist Financial lowered their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Stifel Nicolaus cut their price objective on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $74.94.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,382 shares of company stock valued at $1,917,679 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.